Novo Nordisk A/S
- 거래소
- 미국
- 국가 / 지역
- USA
- 상장일
- 1982년 1월 4일
- 직원 수
- 67,900
종합 밸류에이션 구간 · 보수적 $28–$34 / 적정 $40–$50 / 낙관적 $56–$67. $49.67 기준, 적정 내재가치 구간 내.
보고서 발행 시 $44.74（2026년 5월 17일）
데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; and growth hormone pens and injection needles. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
연혁
Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark, with an IPO date of 1982-01-04. The company researches, manufactures, and distributes pharmaceutical products through two segments, Obesity and Diabetes Care, and Rare Disease. Its products include GLP-1 medicines such as Ozempic and Wegovy, insulin, the NovoPen 6 and NovoPen Echo Plus smart insulin pens, the Dose Check application, and growth hormone pens. By 2025 it employed about 67,900 people, and Wegovy had launched in more than 55 countries.
업계 내 위치
Novo Nordisk works in the Healthcare sector under Drug Manufacturers - General, operating across Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. In its Q1 2026 materials it described itself as the global volume-share leader in weekly-injectable GLP-1 at about 55%, and as the world's largest manufacturer of insulin and GLP-1. Revenue grew from DKK 122.0 billion in 2019 to DKK 309.1 billion in 2025. Novo Holdings, backed by the Novo Nordisk Foundation, holds 28.05% of capital and 77.28% of voting rights.
이 종목에 대한 리포트가 아직 해당 언어로 없습니다.